|
Name of the product: TOBRADOSA
Active ingredient: Tobramycin 300 mg
Dosage form: inhalation solution
Dispensing requirements: Rx only
Argentine Industry
Composition:
Each millilitre of solution contains tobramycin 60 mg, sodium chloride, sulphuric acid, and sterile water for injection.
Indications:
TOBRADOSA is indicated for patients with cystic fibrosis with Pseudomonas aeruginosa. TOBRADOSA has been specifically formulated to be administered by inhalation; following inhalation, TOBRADOSA is concentrated in the airways.
Therapeutic action:
Antibiotic.
Storage:
The stability of TOBRADOSA inhalation solutions kept in the marketed packing is 24 months at temperature between 2º and 8º C, and 28 days at temperature below 25º C.
Marketed presentations:
TOBRADOSA (tobramycin 300 mg/5 ml):
Packs containing 28 single-dose pouches.
Packs containing 56 single-dose pouches.
Medicinal speciality authorised by the Ministry of Health.
Certificate Nº 51910
Laboratorio DOSA S.A.
Girardot 1369, (C1427AKC) Buenos Aires, Argentine
Pharmaceutical Director: María C. Terzo, Pharmacist
|
; EffectiveNewWin.focus(); "tobradosa 300 x 56")